Lindsay V.M. Leek

Lindsay V.M. Leek

Auto-generated profile, based on publicly available information

Lindsay V.M. Leek

Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
TBThomas W. Battaglia
Thomas W. Battaglia
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
GWGijs F. de Wit
Gijs F. de Wit
EVE.E. Voest
E.E. Voest
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches. Patients and Methods: Patients with dMMR/MSI tumors who exhausted standard-of-care treatment options were enrolled in the Drug Rediscovery Protocol, a pan-cancer clinical trial that treats patients with cancer based on their tumor molecular profile with off-label anticancer drugs (NCT02925234). Patients received nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks). The primary endpoint was clinical benefit (CB: objective response or stable disease ≥16 weeks). Whole-genome sequencing and RNA sequencing were performed on pretreatment tumor biopsies. Results: A total of 130 evaluable patients were enrolled with 16 different cancer types. CB was observed in 62% [95% confidence interval (CI), 53–70], with an objective response in 45% (95% CI, 36–54). After a median follow-up of 14.5 months (95% CI, 13–19), the median progression-free survival was 18 months (95% CI, 9–not reached), and the median overall survival was not reached. Whereas CB was not, or only weakly, associated with markers of adaptive immune cell infiltration, CB was strongly associated with expression of a broad set of innate immune receptors/ligands. This clearly contrasted findings in melanoma, in which markers of adaptive immunity dominated the biomarker landscape. Conclusions: Nivolumab proved highly effective in advanced dMMR/MSI tumors. Expression of key innate immune receptors/ligands was the main predictor of a good treatment outcome, contrasting findings in melanoma and strengthening the rationale for tumor type–specific biomarkers for guiding immunotherapy.

17 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BGBirgit S. Geurts
Birgit S. Geurts
LZLaurien J. Zeverijn
Laurien J. Zeverijn
LLLindsay V.M. Leek
Lindsay V.M. Leek
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
LHLouisa R. Hoes
Louisa R. Hoes
EVE.E. Voest
E.E. Voest
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing–based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included in the Drug Rediscovery Protocol (NCT02925234). Patients and Methods: Patients with solid, treatment-refractory, microsatellite-stable tumors were enrolled in cohort A: breast cancer cohort harboring a TML of 140 to 290, cohort B: tumor-agnostic cohort harboring a TML of 140 to 290, and cohort C: tumor-agnostic cohort harboring a TML >290. Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint was clinical benefit [CB; objective response or stable disease (SD) ≥16 weeks]. Pretreatment tumor biopsies were obtained for whole-genome sequencing and RNA sequencing. Results: Seventy-two evaluable patients with 26 different histotypes were enrolled. The CB rate was 13% in cohort A [3/24 with partial response (PR)], 21% in cohort B (3/24 with SD; 2/24 with PR), and 42% in cohort C (4/24 with SD; 6/24 with PR). In cohort C, neoantigen burden estimates and expression of inflammation and innate immune biomarkers were significantly associated with CB. Similar associations were not identified in cohorts A and B. In cohort A, CB was significantly associated with mutations in the chromatin remodeling gene PBRM1, whereas in cohort B, CB was significantly associated with expression of MICA/MICB and butyrophilins. CB and clonal TML were not significantly associated. Conclusions: Although pembrolizumab lacked activity in cohort A, cohorts B and C met the study’s primary endpoint. Further research is warranted to refine the selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity. See related commentary by Hsu and Yen, p. 3652

1 October 2024
Verified
Other
Open access
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
TBThomas W. Battaglia
Thomas W. Battaglia
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
GWGijs F. de Wit
Gijs F. de Wit
EVE.E. Voest
E.E. Voest
Supplementary Table S1. Representativeness of study participants.

1 October 2024
Verified
Other
Open access
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
TBThomas W. Battaglia
Thomas W. Battaglia
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
GWGijs F. de Wit
Gijs F. de Wit
EVE.E. Voest
E.E. Voest
Supplementary Table S3. Baseline characteristics and clinical outcome data of evaluable dMMR/MSI patients treated with nivolumab in high tumor mutational load cohort.

1 October 2024
Verified
Other
Open access
PDF file
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
TBThomas W. Battaglia
Thomas W. Battaglia
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
GWGijs F. de Wit
Gijs F. de Wit
EVE.E. Voest
E.E. Voest
Supplementary Figure S1. Accrual flowchart including reasons for ineligibility.

1 October 2024
Verified
Other
Open access
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
TBThomas W. Battaglia
Thomas W. Battaglia
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
GWGijs F. de Wit
Gijs F. de Wit
EVE.E. Voest
E.E. Voest
Supplementary Table S2. Inclusion and exclusion criteria.